腫瘍性キナーゼシグナリング
1The Salk Institute, Molecular and Cell Biology Laboratory, 10010 North Torrey Pines Road, La Jolla, California 92037, USA. blume@salk.edu
Nature
|May 18, 2001
まとめ
タンパク質チロシンキナーゼ (PTKs) は細胞シグナル伝達を調節するが,その緩和が癌を誘発する. このレビューは,異常なPI(3) K/AktおよびmTOR/p70S6K経路がヒトの悪性腫瘍にどのように貢献するかを詳細に説明します.
科学分野:
- 分子生物学は分子生物学である.
- 細胞シグナリング 細胞シグナリング
- 腫瘍学 腫瘍学
背景:
- タンパク質チロシンキナーゼ (PTK) は,細胞のコミュニケーションと発達に不可欠です.
- PTKの活動は通常,厳格に規制され,不調は悪性変異につながる.
- 主要な下流エフェクターには,フォスホイノシチド3OHキナーゼ (PI(3) K) とAkt/p70S6Kが含まれています.
研究 の 目的:
- 発がん性PTKが,自己抑制制御の障害からどのように発生するかを見直す.
- 人間の癌における規制解除されたPI(3)K/AktとmTOR/p70S6Kのシグナル伝達に関する知識を更新する.
主な方法:
- PTKシグナル伝達経路に関する文献レビュー.
- キナーゼ活性に影響する遺伝子変異の分析.
- 癌におけるPI(3) K/AktとmTOR/p70S6K経路に焦点を当てました.
主要な成果:
- 腫瘍性PTKは,正常な自己抑制の喪失から生じる.
- 規制解除されたPI(3) K/Aktシグナリングは,がんにおける一般的なメカニズムです.
- 異常なmTOR/p70S6Kシグナル伝達も悪性腫瘍に大きく寄与する.
結論:
- PTKの規制緩和を理解することは,がん治療において極めて重要です.
- PI(3) K/AktとmTOR/p70S6K経路をターゲットにすることで,治療の可能性が生まれます.
- がん治療のために,キナーゼ調節に関するさらなる研究が必要である.
関連する概念動画
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...